Spanish SEFC Eyes Up Drug Evaluation Overhaul Through “Multidisciplinary Collaboration”

Date: April 8, 2021 | Country: SPAIN | Region: EUROPE | Type: Policy | Keywords: #collaboration #economic #evaluation #sefc #sns #spain #therapeuticpositioningreport

PRICENTRIC BRIEF:

  • The Spanish Society of Clinical Pharmacology (SEFC) has revealed plans to revamp its drug evaluation process, including its methods of selecting and positioning drugs
  • According to the organization, it will reassess the system from “a participatory point of view of multidisciplinary collaboration,” as “the collaboration of different professionals is essential and that leadership must, without a doubt, be shared”
  • In a statement, the group urged health authorities, health professionals such as specialists in different pathologies, pharmacists, pharmacologist, and other professionals such as economists, as well as patients to “collaborate closely” ensure that the most appropriate medicines are provided in the National Health System”

 

THE DETAILS

MADRID, Spain – The Spanish Society of Clinical Pharmacology (SEFC) has revealed plans to revamp its drug evaluation process, including its methods of selecting and positioning drugs.

According to the organization, it will reassess the system from “a participatory point of view of multidisciplinary collaboration,” as “the collaboration of different professionals is essential and that leadership must, without a doubt, be shared.”

In a statement, the group urged health authorities, health professionals such as specialists in different pathologies, pharmacists, pharmacologist, and other professionals such as economists, as well as patients to “collaborate closely” to “ensure that the most appropriate medicines are provided in the National Health System.”

The statement comes following a report from the SEFH in which it supported the idea of improving strategies in the evaluation, selection and positioning of medicines, together with the general direction of the Common Portfolio of Services of the National System of Health and Pharmacy.

Olga Delgado, President of the group, expressed support for actions “that are aligned with the work that Hospital Pharmacists and our Genesis group have been developing, offering to the society as a whole collaboration and accumulated experience in drug evaluation, building a necessary commitment of co-responsibility to be able to achieve the best decision-making on the use of the most effective, safest and most efficient drugs and obtain the best results in health in patients.”

Late last year Patricia Lacruz, Director-General of Basic Portfolio of Services of Spain’s National Health System (SNS) and Pharmacy announced that Spain will be following a new economic model for evaluating innovative medicines.

The initiative, Revalmed-SNS, will include economic evaluations in Spain’s Therapeutic Positioning Reports (TPRs), which will be fundamental for pricing and reimbursement negotiations going forward.

Spanish industry experts have previously suggested that TPRs could potentially help streamline local drug evaluation, following a qualitative study that leaned in favor of the notion. The experts explained that hospital reports and similar documents at the regional level could be completed in a more agile way if TPRs were used as a reference, and so reasoned that they could be used as a tool to facilitate access to new drugs by accelerating the evaluated process.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.